BMRN:NASDAQ
Biomarin Pharmaceutical Inc
$60.00
arrow_upward
+0.22%(+0.13) 1D
$60.50
arrow_upward
+0.83% (+0.50)bedtimeAfter hours
Closed: Sep 30, 4:00:01 PM GMT-4 · USD
search
All symbols
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for BMRN...
Open
$59.90
High
$60.70
Low
$59.37
Mkt. cap
11.61B
Avg. vol.
1.90M
Volume
0.00
P/E ratio
161.76
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.24
Shares outstanding
193.57M
No. of employees
3K
Open
$59.90
High
$60.70
Low
$59.37
Mkt. cap
11.61B
Avg. vol.
1.90M
Volume
0.00
P/E ratio
161.76
52-wk high
$70.98
52-wk low
$49.26
EPS
$0.37
Beta
0.24
Shares outstanding
193.57M
No. of employees
3K
News stories
From web sources and news partners
Simply Wall Street
·
14 minutes ago
BioMarin Pharmaceutical (BMRN) Could Be 35% Undervalued Following Profluent AI Collaboration
The Press Democrat
·
5 hours ago
Major North Bay biotech employer to cut 119 jobs in consolidation move
AD HOC NEWS
·
6 hours ago
BioMarin Pharmaceutical stock weighs VOXZOGO setback against growth
TipRanks
·
8 hours ago
BioMarin Grants Ascendis Global License, Secures Royalty Revenues
Profile
BioMarin Pharmaceutical Inc. is an American biotechnology company headquartered in San Rafael, California. It has offices and facilities in the United States, South America, Asia, and Europe. BioMarin's core business and research are in enzyme replacement therapies. BioMarin was the first company to provide therapeutics for mucopolysaccharidosis type I, by manufacturing laronidase. BioMarin was also the first company to provide therapeutics for phenylketonuria.
Over the years, BioMarin has been criticised for drug pricing and for specific instances of denying access to drugs in clinical trials. Wikipedia
About Biomarin Pharmaceutical Inc
CEOAlexander Hardy
Employees3.22K
FoundedMar 1997
HeadquartersSan Rafael, California, United States
SectorBiotechnology
Websitebiomarin.com